Trial registration number
|
ChiCTR2100051684 |
Full text link
Last imported at : Oct. 28, 2021, noon
Source : International Clinical Trials Registry Platform (ICTRP)
|
http://www.chictr.org.cn/showproj.aspx?proj=134505
|
First author
Last imported at : Oct. 28, 2021, noon
Source : International Clinical Trials Registry Platform (ICTRP)
|
Ke Hu
|
Contact
Last imported at : Oct. 28, 2021, noon
Source : International Clinical Trials Registry Platform (ICTRP)
|
huke-rmhospital@163.com
|
Registration date
Last imported at : Oct. 28, 2021, noon
Source : International Clinical Trials Registry Platform (ICTRP)
|
2021-09-30
|
Recruitment status
Last imported at : Oct. 28, 2021, noon
Source : International Clinical Trials Registry Platform (ICTRP)
|
Recruiting
|
Study design
Last imported at : Oct. 28, 2021, noon
Source : International Clinical Trials Registry Platform (ICTRP)
|
RCT
|
Allocation
Last imported at : Oct. 28, 2021, noon
Source : International Clinical Trials Registry Platform (ICTRP)
|
Randomized
|
Design
Last imported at : Oct. 28, 2021, noon
Source : International Clinical Trials Registry Platform (ICTRP)
|
Parallel
|
Masking
Last imported at : Oct. 28, 2021, noon
Source : International Clinical Trials Registry Platform (ICTRP)
|
Open label
|
Center
Last imported at : Oct. 28, 2021, noon
Source : International Clinical Trials Registry Platform (ICTRP)
|
single-center
|
Study aim
Last imported at : Oct. 28, 2021, noon
Source : International Clinical Trials Registry Platform (ICTRP)
|
Treatment
|
Inclusion criteria
Last imported at : Oct. 28, 2021, noon
Source : International Clinical Trials Registry Platform (ICTRP)
|
1. Male and female, aged 18-70 years,
2. Novel coronavirus nucleic acid test positive,
3. The diagnostic criteria for confirmed cases in the national COVID-19 Protocol (Eighth edition) were met,
4. Onset within 7 days (severe cases can be extended to less than 10 days),
5. The informed consent is signed by patients or their authorized agent,
6. Subjects who may or receive oral medication,
7. Agree to collect clinical samples,
8. Female subjects of reproductive age were not pregnant and agreed to use effective contraception within 7 days of the last oral medication to ensure non-pregnancy,
9. The men agreed not to cohabit with the woman for seven days after the last oral medication.
|
Exclusion criteria
Last imported at : Oct. 28, 2021, noon
Source : International Clinical Trials Registry Platform (ICTRP)
|
1. Severe vomiting and difficulty in taking or ingestion of oral medication,
2. Pregnant and lactating women,
3. People with mental illness and cognitive impairment,
4. Subjects received antiviral drugs (including interferon-alpha, ribavirin, chloroquine phosphate, Abidol, remdesivir, lopinavir/ritonavir, monoclonal antibodies) in the week before admission,
5. Cases of respiratory failure requiring mechanical ventilation,
6. There were cases of shock,
7. ICU care is required for other organ failure,
8. Patients who were clinically predicted to have no hope of survival and were placed on hospice care only, or those who were in a deep coma and did not respond to supportive treatment within three hours of admission.
|
Number of arms
Last imported at : Oct. 28, 2021, noon
Source : International Clinical Trials Registry Platform (ICTRP)
|
2
|
Funding
Last imported at : Oct. 28, 2021, noon
Source : International Clinical Trials Registry Platform (ICTRP)
|
Renmin Hospital of Wuhan University
|
Inclusion age min
Last imported at : Oct. 28, 2021, noon
Source : International Clinical Trials Registry Platform (ICTRP)
|
18
|
Inclusion age max
Last imported at : Oct. 28, 2021, noon
Source : International Clinical Trials Registry Platform (ICTRP)
|
70
|
Countries
Last imported at : Oct. 28, 2021, noon
Source : International Clinical Trials Registry Platform (ICTRP)
|
China
|
Type of patients
Last imported at : Oct. 28, 2021, noon
Source : International Clinical Trials Registry Platform (ICTRP)
|
Moderate/severe disease at enrollment
|
Severity scale
Last imported at : Oct. 28, 2021, noon
Source : International Clinical Trials Registry Platform (ICTRP)
|
4: Moderate/severe disease at enrollment
|
Total sample size
Last imported at : Oct. 28, 2021, noon
Source : International Clinical Trials Registry Platform (ICTRP)
|
60
|
primary outcome
Last imported at : Oct. 28, 2021, noon
Source : International Clinical Trials Registry Platform (ICTRP)
|
Time for viral nucleic acid to turn negative;
|
Notes
Last imported at : Oct. 28, 2021, noon
Source : International Clinical Trials Registry Platform (ICTRP)
|
| Declared number of arm (2.0)
differs from found arms (3.0)
|
Phase
Last imported at : Oct. 28, 2021, noon
Source : International Clinical Trials Registry Platform (ICTRP)
|
Phase 3
|
Arms
Last imported at : Oct. 28, 2021, noon
Source : International Clinical Trials Registry Platform (ICTRP)
|
[{"arm_notes": "Oral+inhaled", "treatment_id": 2020, "treatment_name": "Interferon alpha+leflunomide", "treatment_type": "Interferons+other targeted therapies", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "Inhaled", "treatment_id": 664, "treatment_name": "Interferon alpha", "treatment_type": "Interferons", "pharmacological_treatment": "Pharmacological treatment"}]
|